Yuhan touts benefits of promising new P-CAB molecule as it seeks partners
This article was originally published in Scrip
Executive Summary
Yuhan Corp is encouraged by what it says are "very promising" early clinical results for an in-house developed potassium-competitive acid blocker (P-CAB), which it is now planning to take into a Phase II trial programme in patients with gastro-oesophageal reflux disease.